Striatal Substance P Reduces Acute but Not Chronic Inflammatory Pain in Rats
Substance P infused into the striatum relieved inflammatory pain at 3 days but not 7 days, because persistent inflammation downregulated NK1 receptors in the brain.
Quick Facts
What This Study Found
Striatal substance P via NK1 receptors provides antinociception in acute (3-day) but not subacute (7-day) inflammatory pain, due to inflammation-induced NK1 receptor downregulation.
Key Numbers
Day 3: SP reduced allodynia (NK1R-dependent); Day 7: SP ineffective; NK1R protein decreased at day 7; paw edema unaffected
How They Did This
Animal study using reverse microdialysis to continuously infuse substance P into rat dorsal striatum, measuring mechanical allodynia and paw edema at 3 and 7 days after CFA-induced inflammation, with NK1 receptor protein quantification.
Why This Research Matters
Understanding when neuropeptide pain pathways work — and when they stop working — is critical for developing effective pain treatments and understanding why chronic pain becomes treatment-resistant.
The Bigger Picture
This study reveals that persistent inflammation can downregulate the brain's own pain-relief neuropeptide receptors, potentially explaining why chronic pain becomes harder to treat over time.
What This Study Doesn't Tell Us
Rat model with direct brain infusion — not a practical delivery route; single inflammatory model (CFA); mechanism of NK1 downregulation not fully characterized.
Questions This Raises
- ?Can NK1 receptor downregulation be prevented to maintain substance P pain relief during chronic inflammation?
- ?Does this receptor downregulation occur in human chronic pain conditions?
- ?Could early substance P intervention prevent the transition from acute to chronic pain?
Trust & Context
- Key Stat:
- Effective at day 3, not day 7 Persistent inflammation downregulated striatal NK1 receptors, eliminating substance P antinociceptive effect
- Evidence Grade:
- Well-controlled animal study with pharmacological validation and receptor protein measurements, but limited to one pain model and invasive delivery route.
- Study Age:
- Published in 2020; complements the parallel study on substance P in neuropathic pain (same research group).
- Original Title:
- Continuous infusion of substance P inhibits acute, but not subacute, inflammatory pain induced by complete Freund's adjuvant.
- Published In:
- Biochemical and biophysical research communications, 533(4), 971-975 (2020)
- Authors:
- Nakamura, Yoki(2), Fukushige, Ryo(2), Watanabe, Kohei(2), Kishida, Yuki, Hisaoka-Nakashima, Kazue, Nakata, Yoshihiro, Morioka, Norimitsu
- Database ID:
- RPEP-05022
Evidence Hierarchy
Frequently Asked Questions
Can substance P reduce pain?
When infused into certain brain regions, substance P can reduce inflammatory pain through NK1 receptor activation, but this effect diminishes as the inflammation becomes chronic and receptors downregulate.
Why does pain become harder to treat over time?
This study shows persistent inflammation can downregulate neuropeptide receptors in the brain, making the natural pain-relief system less responsive — a possible mechanism for chronic pain treatment resistance.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05022APA
Nakamura, Yoki; Fukushige, Ryo; Watanabe, Kohei; Kishida, Yuki; Hisaoka-Nakashima, Kazue; Nakata, Yoshihiro; Morioka, Norimitsu. (2020). Continuous infusion of substance P inhibits acute, but not subacute, inflammatory pain induced by complete Freund's adjuvant.. Biochemical and biophysical research communications, 533(4), 971-975. https://doi.org/10.1016/j.bbrc.2020.09.113
MLA
Nakamura, Yoki, et al. "Continuous infusion of substance P inhibits acute, but not subacute, inflammatory pain induced by complete Freund's adjuvant.." Biochemical and biophysical research communications, 2020. https://doi.org/10.1016/j.bbrc.2020.09.113
RethinkPeptides
RethinkPeptides Research Database. "Continuous infusion of substance P inhibits acute, but not s..." RPEP-05022. Retrieved from https://rethinkpeptides.com/research/nakamura-2020-continuous-infusion-of-substance
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.